KLTO (Klotho Neurosciences) Total Liabilities: $0.15 Mil (As of Sep. 2025)


KLTO Klotho Neurosciences Inc KLTO
22 GF Score
Price $0.52
! 1 Warning Sign
View Full Analysis

What is Klotho Neurosciences Total Liabilities?

Klotho Neurosciences KLTO 22 Total Liabilities is $0.15 Mil as of Sep. 2025. GuruFocus rates KLTO with a GF Score™ of 22/100. The stock has 1 warning sign investors should review.

Klotho Neurosciences's Total Liabilities for the quarter that ended in Sep. 2025 was $0.15 Mil.

Klotho Neurosciences's quarterly Total Liabilities declined from Mar. 2025 ($2.35 Mil) to Jun. 2025 ($0.20 Mil) and declined from Jun. 2025 ($0.20 Mil) to Sep. 2025 ($0.15 Mil).

Klotho Neurosciences's annual Total Liabilities increased from Dec. 2022 ($1.36 Mil) to Dec. 2023 ($1.62 Mil) but then declined from Dec. 2023 ($1.62 Mil) to Dec. 2024 ($1.27 Mil).

Klotho Neurosciences Total Liabilities Historical Data

* Premium members only.

The historical data trend for Klotho Neurosciences's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Klotho Neurosciences Total Liabilities Chart

Klotho Neurosciences Annual Data
Trend Dec21 Dec22 Dec23 Dec24
Total Liabilities
0.02 1.36 1.62 1.27

Klotho Neurosciences Quarterly Data
Dec21 Jun22 Dec22 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.00 1.27 2.35 0.20 0.15
KLTO
22GF Score
Klotho Neurosciences Inc KLTO
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Klotho Neurosciences Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Klotho Neurosciences's Total Liabilities for the fiscal year that ended in Dec. 2024 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=1.248+(0+0.024
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=1.27

Total Liabilities=Total Assets (A: Dec. 2024 )-Total Equity (A: Dec. 2024 )
=2.457-1.185
=1.27

Klotho Neurosciences's Total Liabilities for the quarter that ended in Sep. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=0.093+(0+0.053
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=0.15

Total Liabilities=Total Assets (Q: Sep. 2025 )-Total Equity (Q: Sep. 2025 )
=10.073-9.927
=0.15

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $0.15 Mil mean?
Klotho Neurosciences (KLTO) has a Total Liabilities of $0.15 Mil as of Sep. 2025. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Klotho Neurosciences and its competitors.
Is Klotho Neurosciences' Total Liabilities too high?
Klotho Neurosciences' current Total Liabilities is $0.15 Mil. Overall, Klotho Neurosciences has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Klotho Neurosciences' Total Liabilities compare to KTTA and JUNS?
Klotho Neurosciences' Total Liabilities of $0.15 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Klotho Neurosciences and its competitors. Klotho Neurosciences's current Total Liabilities is $0.15 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Klotho Neurosciences stock overvalued right now?
Klotho Neurosciences (KLTO) has a current Total Liabilities of $0.15 Mil. The current Total Liabilities is $0.15 Mil. Klotho Neurosciences' overall GF Score™ is 22/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Klotho Neurosciences (KLTO), the current Total Liabilities is $0.15 Mil as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Klotho Neurosciences Business Description

Address 13576 Walnut Street, Suite A, Omaha, NE, USA, 68144
Klotho Neurosciences Inc is in the development of essential medicines for the treatment of chronic diseases: Cancer, Cardiovascular, and Neurodegenerative disorders. The Company currently has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and a proprietary, patented gene therapy platform which uses a gene therapy approach to introduce a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases. Company pipeline includes KLTO 101, KLTO 202, KLTO 301.
22GF Score

Get the complete analysis for KLTO

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.52
Price